Abstract
Sarcomas are a class of tumors defined by their mesenchymal origin that comprise very different neoplasms. Although some sarcomas harbor pathogenomic molecular alterations (i.e. specific balanced translocations and their associated chimeric fusion genes), others still lack an ultimate diagnostic tool, which could be of great interest as in some cases different sarcomas share a similar clinical manifestation. High throughput tools are contributing new ways to molecularly delineate the boundaries of each sarcoma subtype. Moreover, they are also shedding light into other research subjects of immediate concern: (i) the elucidation of the molecular targets of chimeric fusion proteins and their interactome; (ii) the discovery of new biomarkers and therapeutic targets; and (iii) the delineation of the response to therapeutic agents. Here we review the application of proteomics approaches to sarcomas, with special emphasis in Ewing sarcoma. Proteomics strategies offer the focus, the analytical potential, and the high throughput capabilities to decipher the hidden agenda of the biology of sarcomas, a knowledge that will surely be the subject of future patents intended to develop new diagnostic and therapeutic tools.
Keywords: 2-DE, Cancer, cell signaling, chimeric fusion protein, chromosomal translocation, diagnostic tools, DIGE, Ewing sarcoma, EWS-FLI1, MALDI-ToF, mass spectrometry, molecular targets, oncogene, protein microarrays, proteomics, sarcomas, sarcomagenesis, targets of therapy.
Recent Patents on Biotechnology
Title:Mining Sarcomas by Proteomics Approaches: Ewing Sarcoma on the Spotlight
Volume: 7 Issue: 2
Author(s): Carlos Mackintosh and Juan Madoz-Gúrpide
Affiliation:
Keywords: 2-DE, Cancer, cell signaling, chimeric fusion protein, chromosomal translocation, diagnostic tools, DIGE, Ewing sarcoma, EWS-FLI1, MALDI-ToF, mass spectrometry, molecular targets, oncogene, protein microarrays, proteomics, sarcomas, sarcomagenesis, targets of therapy.
Abstract: Sarcomas are a class of tumors defined by their mesenchymal origin that comprise very different neoplasms. Although some sarcomas harbor pathogenomic molecular alterations (i.e. specific balanced translocations and their associated chimeric fusion genes), others still lack an ultimate diagnostic tool, which could be of great interest as in some cases different sarcomas share a similar clinical manifestation. High throughput tools are contributing new ways to molecularly delineate the boundaries of each sarcoma subtype. Moreover, they are also shedding light into other research subjects of immediate concern: (i) the elucidation of the molecular targets of chimeric fusion proteins and their interactome; (ii) the discovery of new biomarkers and therapeutic targets; and (iii) the delineation of the response to therapeutic agents. Here we review the application of proteomics approaches to sarcomas, with special emphasis in Ewing sarcoma. Proteomics strategies offer the focus, the analytical potential, and the high throughput capabilities to decipher the hidden agenda of the biology of sarcomas, a knowledge that will surely be the subject of future patents intended to develop new diagnostic and therapeutic tools.
Export Options
About this article
Cite this article as:
Mackintosh Carlos and Madoz-Gúrpide Juan, Mining Sarcomas by Proteomics Approaches: Ewing Sarcoma on the Spotlight, Recent Patents on Biotechnology 2013; 7 (2) . https://dx.doi.org/10.2174/18722083113079990004
DOI https://dx.doi.org/10.2174/18722083113079990004 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
Call for Papers in Thematic Issues
Advancements in Plant Genetics and Genomics
This thematic issue will highlight cutting-edge innovations and recent patents across the breadth of plant genetics and genomics. Key topics will include advanced breeding techniques, omics-based approaches, gene editing, trait discovery, and translational applications for crop improvement. Renowned researchers from leading institutions worldwide will provide state-of-the-art insights and future perspectives ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gene Therapy to Overcome Drug Resistance in Cancer: Targeting Key Regulators of the Apoptotic Pathway
Current Gene Therapy QSPR and Flow Cytometry Analysis (QSPR-FCA): Review and New Findings on Parallel Study of Multiple Interactions of Chemical Compounds with Immune Cellular and Molecular Targets
Current Drug Metabolism Nano Approaches to Enhance Pharmacokinetic and Pharmacodynamic Activity of Plant Origin Drugs
Current Nanoscience The Medicinal Chemistry of Theragnostics, Multimodality Imaging and Applications of Nanotechnology in Cancer
Current Topics in Medicinal Chemistry IgG4-Related Disease (IgG4+MOLPS) – Diagnostic Criteria and Diagnostic Problems
Current Immunology Reviews (Discontinued) Process Variables and Design of Experiments in Liposome and Nanoliposome Research
Mini-Reviews in Medicinal Chemistry Recent Advances in PUVA Photochemotherapy and PDT for the Treatment of Cancer
Current Pharmaceutical Design Protein Kinases as Drug Targets in Human and Animal Diseases
Current Enzyme Inhibition The Activating Receptors of Natural Killer Cells and Their Inter-Switching Potentials
Current Drug Targets Selective Activation of Intracellular Signalling Pathways in Dendritic Cells for Cancer Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry Beneficial Action of Citrus Flavonoids on Multiple Cancer-Related Biological Pathways
Current Cancer Drug Targets Pathological and Therapeutic Aspects of Long Noncoding RNAs in Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry A Review of Studies on Targeting Interleukin 4 Receptor for Central Nervous System Malignancy
Current Molecular Medicine Nanocarriers for Anticancer Drugs - New Trends in Nanomedicine
Current Drug Metabolism Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?
Current Drug Targets Proteases and their Receptors as Mediators of Inflammation-Associated Colon Cancer
Current Pharmaceutical Design Drug Targeting Systems for Cancer Therapy: Nanotechnological Approach
Mini-Reviews in Medicinal Chemistry Traditional Chinese Medicines (TCMs) for Molecular Targeted Therapies of Tumours
Current Drug Discovery Technologies <sup>109</sup>Pd labeled 5,10,15,20-tetrakis[4-carboxymethyleneoxyphenyl]porphyrin: a Potential Agent for Targeted Tumor Therapy
Current Radiopharmaceuticals